Project Grant W81XWH1710057

The National Institute of Neurological Disorders and Stroke (NINDS) awarded Aquinnah Pharmaceuticals, Inc. a $1,499,212 Project Grant (CFDA 93.853) to develop a novel oral brain-penetrant therapeutic for Amyotrophic Lateral Sclerosis (ALS). The funding will support manufacturing, IND-enabling studies, and a PIND meeting with the FDA for this innovative new clinical drug candidate designed to slow and potentially reverse ALS disease progression. The proposed therapeutic targets the key...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013.00 to the University of Southern California to develop a new therapeutic monoclonal antibody targeting isoaspartylated ELAVL4 protein for the treatment of small cell lung cancer (SCLC). The key objectives are to: 1) Generate a mouse monoclonal antibody specifically binding to isoaspartylated ELAVL4, which is expressed on the surface of SCLC tumors and can trigger an...

The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...

This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) will provide $6,133,297 to Mayo Clinic Jacksonville to establish an Expanded Access Program (EAP) that offers the experimental drug ibudilast to 200 amyotrophic lateral sclerosis (ALS) patients over 6 months. The project will develop a network of ALS physicians to manage the EAP, which will feature self-activation, streamlined workflows, home-based evaluations,...

This Project Grant award, valued at $558,182 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS). The research team at The Washington University will develop advanced proteomic assays to analyze neurofilament isoforms and...

This $2,147,016 project grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and validation of a blood-based biomarker test for amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders. The awardee, Neurodex Inc., aims to validate analytical methods for their EXOSORT technology, which isolates neuron-derived extracellular...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $124,246 to the University of Massachusetts Medical School to develop advanced base and prime editing strategies to correct common SOD1 gene mutations that cause amyotrophic lateral sclerosis (ALS). The key objectives are to: (1) develop AAV-mediated base editing gene correction...

The University of Texas Medical Branch at Galveston will research immunotherapy targeting tau aggregate polymorphs under a $4.02 million project grant from the National Institute on Aging's Aging Research program (CFDA 93.866). The three-year award will support determining the efficacy of four monoclonal antibodies in targeting disease-relevant tau oligomeric strains/polymorphs implicated in neurodegenerative tauopathies like Alzheimer's disease and frontotemporal lobar degeneration. Researchers...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, is focused on developing a novel phosphorodiamidate morpholino oligonucleotide (PMO) RNA therapeutic to treat Alzheimer's disease (AD). The $238,500 award, running from December 1, 2024 to November 30, 2026, aims to create a highly effective PMO therapeutic that can selectively target the amyloid precursor protein (APP) to prevent the buildup of amyloid...

The Research Foundation for the State University of New York (RF-SUNY) was awarded $768,825 under the Military Medical Research and Development grant program (CFDA 12.420) by the Defense Health Agency to test RNA aptamers in the SOD1 G93A ALS mouse model from September 1, 2023 to August 31, 2025. This funding will support RF-SUNY's research at the University at Albany to investigate medical solutions for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, by exploring the...